JUPITER, FL,
Feb. 22, 2011
(PRNewswire) -
Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has launched FibreZyme® G200, a next generation, high performance enzyme designed to improve paper quality and improve the economics of various pulp and paper manufacturing processes.
Brian Murdoch, Dyadic's Senior Director Sales & Technical Development stated, "FibreZyme® G200 is a great addition to our product portfolio and provides further evidence of the value-adding capabilities of Dyadic's C1 platform technology. FibreZyme® G200 operates under wide pH and temperature ranges allowing for seamless integration into most pulp and paper manufacturing processes."
Specific attributes of FibreZyme® G200 include the following:
Reduces fiber raw material costs and petroleum-derived chemical usages
Reduces pulp refining energy requirements
Increases paper machine production rates and efficiencies
Improves softness in tissue production
Enhances pulp drainage rates and reduces paper drying demand
Enhances and restores fiber strength and increases inter-fiber bonding through fibrillation
New Production Platform
FibreZyme® G200 is produced using a new variant of Dyadic's patented and proprietary C1 platform technology which Dyadic refers to as the "white strain." Developed through sustained research efforts at Dyadic Netherlands, the white strain produces significantly less background proteins. These changes allow for more efficient and economical industrial scale production of highly targeted enzymes and proteins at greater purity levels.
Richard Jundzil, Dyadic's Vice President Operations stated, "FibreZyme® G200 represents the first product commercialized using the new C1 white strain. We now have in place all the molecular tools, scale-up experience and production processes necessary to support additional timely market introductions of new enzymes identified from the C1 and other genomes. Dyadic intends to utilize the white strain production platform to create a sustainable and more diverse product portfolio. We also intend to express new enzyme and protein targets with our collaborative partners in a variety of industries."
